Episode
Slowing Disability in MS
- Podcast
- The Bio Report
- Published
- Apr 22, 2026
- Duration seconds
- 1758
- Processing state
not_requested- Canonical source
- https://thebioreport.podbean.com/e/slowing-disability-in-ms/
Actions
POST https://stenobird.com/v1/public/podcasts/the-bio-report-1092382/episodes/slowing-disability-in-ms/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-bio-report-1092382/slowing-disability-in-ms.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Most existing therapies for multiple sclerosis do a good job of reducing relapses and inflammatory activity, but they largely fail to stop the slow neurodegeneration that drives long-term disability, especially in progressive forms of the disease. Immunic Therapeutics is trying to reshape the treatment landscape for multiple sclerosis with its experimental once-daily oral therapy, designed not only to curb inflammation and relapses but also to tackle the neurodegeneration that silently drives disability progression in both relapsing and progressive forms of MS. Daniel Vitt, CEO of Immunic, discusses how the company’s experimental MS therapy works, how it may protect neurons from cell death, and the potential for its dual mechanism of action to change the treatment landscape.